5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
about
Human genetics and genomics a decade after the release of the draft sequence of the human genomeDNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosisDNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation statusSuccessful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reportsLow-dose azacitidine after allogeneic stem cell transplantation for acute leukemiaPrognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.Aberrant DNA methylation in malignant melanomaEpigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategiesAn integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancerA prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndromeContinuous zebularine treatment effectively sustains demethylation in human bladder cancer cellsTopotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndromeToxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site.Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma.Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer.Epigenomics in cancer management.Anticancer Natural Compounds as Epigenetic Modulators of Gene ExpressionCharacterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation.Mechanisms of 5-azacytidine (5AzC)-induced toxicity in the rat foetal brain.The relationship between DNA methylation and Reprimo gene expression in gastric cancer cells.
P2860
Q21245451-AFE97727-4B0C-49B3-A7BD-D0FEA6864C53Q28484901-E99B07FF-2D54-4AAF-B14F-E5A0471C8A55Q28544885-8FBC5D3B-EC9D-4439-B6E5-C11DB20E5AD0Q33407141-03B5A6E2-46EE-435C-9C7E-9955E1CD6732Q33861150-D86995E4-DD91-408E-8B33-79E19301AB1BQ33903052-20D3C38C-158A-48A7-B31A-0548619A1F78Q34516587-D209D77E-6BF4-4A4C-955B-E5B46898F94AQ34643306-F93173DA-EFB6-4D3D-89B4-D8B61AF79938Q34768789-4FA24965-842A-4826-8097-886221A75D27Q34802527-D973F3C2-53AD-4D50-AB18-B72EB2C3D55BQ35265834-711226FE-A81B-4FAF-9017-0975FBE98BBCQ35545116-15E606AE-7DA0-4F5E-BFC0-66BB0E1F9E69Q35937752-045B41BC-CFD7-4188-9EF9-E55286938EEFQ35939534-3266DA53-6A2F-4519-89D1-EA35054824D3Q36397293-4AFECC23-108B-4931-B0ED-01DCF1DF2EBEQ36934269-2A2C40C4-E9AE-4B33-9F83-B38370B53E7AQ37374120-76208DDB-7489-4819-8D14-3EFC8F8F43D0Q37376261-63DEE226-C17B-49AD-BF91-9D4A701E1FAAQ37628234-00395B3A-25E9-4033-9692-4C09AD517E89Q37824255-6AFB7627-4C50-4196-8E34-6BFB3C677033Q39214234-9E389C44-C3CD-485D-95BF-AE03C1BBA294Q41480926-018EC324-5672-4812-8CEF-A919BF1437A1Q41966277-A1ABF6BA-AF52-45A3-973F-D98E75387549Q44181995-0BCF3CDD-86D5-458C-9A4B-7D9FD1D99D7BQ47193788-15317BC8-9E45-44AF-B1B0-DFCF2B858A34
P2860
5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
description
1993 nî lūn-bûn
@nan
1993 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@ast
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@en
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@nl
type
label
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@ast
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@en
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@nl
prefLabel
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@ast
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@en
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@nl
P1433
P1476
5-Aza-2'-deoxycytidine (Decita ...... st, present and future trends.
@en
P2093
P478
P577
1993-05-01T00:00:00Z